ACIU AC Immune SA

10.92
-0.28  -3%
Previous Close 11.20
Open 11.15
Price To book 4.94
Market Cap 621590883
Shares 56,922,242
Volume 98,809
Short Ratio 10.73
Av. Daily Volume 61,571

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiation announced February 28, 2017.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 trial to commence 2017.
ACI-35 (anti-tau vaccine)
Alzheimer’s disease
Phase 1/2 completion of recruitment of low-dose cohort noted September 12, 2017.
ACI-24 (anti-Abeta vaccine)
Alzheimer’s disease
Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 1
Alzheimer’s disease

Latest News

  1. AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME
  2. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : September 5, 2017
  3. AC Immune SA – Value Analysis (NASDAQ:ACIU) : August 30, 2017
  4. Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia
  5. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : August 23, 2017
  6. AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES
  7. AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
  8. AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
  9. AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING
  10. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : June 26, 2017
  11. AC Immune SA :ACIU-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
  12. AC Immune reports 1Q loss
  13. AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
  14. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017
  15. Roche to start new trial of AC Immune drug against Alzheimer's